Business Wire

Digital Workshop: Autodoc Launches the Autodoc Club Innovative Platform

29.10.2019 10:00:00 EET | Business Wire | Press release

Share

Autodoc, the benchmark in the online retailing for car spare parts in Europe, is now offering its customers and interested parties an innovative platform for the maintenance of their own car under the name “Autodoc Club”. Thanks to its features, it is unique on the market. The platform, which is available in 26 European countries, contains over 1,300 professional PDF repair instructions in all national languages, plus 2,240 detailed video tutorials. In addition, there is a whole range of other useful functions, such as the integrated maintenance protocol for your own car. This opens up new possibilities for planning repairs and controlling costs. The Autodoc Club app is scheduled for release for Android and iOS operating systems at the beginning of 2020, and bundles on mobile devices all the Club website functions for smartphone and tablet users.

One-stop shop for advice, service and parts

Autodoc’s “Autodoc Club” now offers its customers an innovative platform that provides a wide range of services related to the repair and maintenance of cars. In addition to instructions in the form of PDFs and video tutorials, Autodoc Club offers various other features: users can not only store their car model in their profile, but also keep a maintenance log, receive reminders for the replacement of consumables or save workshop information.

The main component of the new Autodoc Club is a collection of over 1,300 PDF repair manuals and 2,240 video tutorials on individual repairs. A search function enables the customer to find the right manual for their car for the upcoming project. If a manual is not yet available, it can be requested directly from the Autodoc specialists.

Professional advice and convenient purchase of spare parts

The instructions provide direct access to the Autodoc online shop. The user can order all required parts conveniently in the spare parts dealer’s online shop. If a tool is missing, it can also be ordered directly in the online shop. In case of questions regarding repairs or spare parts, the customer can contact specialists such as car mechanics or technicians directly in the forum at any time. Autodoc Club therefore offers an integrated one-stop solution for car owners who want to repair their car themselves or obtain comprehensive information and buy spare parts directly and inexpensively.

“For the layman, car parts are mostly products that require explanation. From our experience, we know that many customers often have questions and need advice from experts. We now offer such support with the easy-to-use and integrated Autodoc Club platform. Every car owner can see how a repair is done, get help and decide for themselves what support they need from their local workshop. In any case, they can always order parts and tools conveniently from the Autodoc online shop without having to search the Internet for them”, explains Autodoc Managing Director, Alexej Erdle.

Free platform for car-related services

Additional features such as a maintenance log and a reminder function for changing consumables round off the offer and also help to avoid unnecessary costs. As a result, your car always stays in top condition. In the personal area, the user can also store vehicle documents, vehicle insurance policies and their own notes, so that all documents relating to their car are always at hand. And from the beginning of 2020, this will also be possible when on the go and travelling using your smartphone.

The use of the platform is unlimited and independent of placing an order. The creation of a free user account is only required for the personal assistant. Existing registration data for the Autodoc online shop also work on the new portal. Any car data already entered in the store account will also be transferred automatically when registering for Autodoc Club with the same account.

About Autodoc

Autodoc is Europe's leading online dealer for car spare parts. As the fastest-growing company in this sector with sales growth of 63% in the financial year 2018 to around EUR 415 million (2017: EUR 254 million), Autodoc aims to further expand its position. Thanks to its successful expansion, Autodoc is now represented in 25 other European countries in addition to Germany. Autodoc pursues a strong customer focus through social media campaigns, technical support in the respective national language and a current demand-oriented range of almost 2.5 million products from 545 brand manufacturers for 128 car brands. Autodoc GmbH is based in the Berlin district of Lichtenberg and is fully owner-managed. In addition to its headquarters, the company opened a representative office on Kurfürstendamm in May 2019.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Thomas Casper
Head of Press and Public Relations & Communication
Tel.: +49-30-2084-78-237
E-mail: t.casper@autodoc.eu
www.autodoc.de

cometis AG
Matthias Kunz
Tel.: +49-611-20-585-564
kunz@cometis.de
www.cometis.de

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release

Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye